District of Columbia; General Obligation, State GO Oct 00

  • ID: 1930718
  • October 2000
  • Standard & Poors
1 of 3

The rating on the District of Columbia's GO debt is based on the district's full faith and credit pledge and reflects improved financial and administrative factors, resulting largely from federal legislation affecting the district and expectations of strengthened management controls and reforms; economic development initiatives; and other factors that will lead to solid credit fundamentals over the long term. Other rating characteristics include debt pressures and an economy that is showing signs of coming out of a long-term decline. A critical component to the improvement in the district's creditworthiness was the implementation of the National Capital Revitalization and Self-Government Improvement Act of 1997. With this act, effective Oct. 1, 1997, the federal government assumed the majority of the district's unfunded...

Companies mentioned in this report are:
- District of Columbia

Action: Affirmed

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research Type: Full Analysis

Note: Product cover images may vary from those shown
2 of 3

- District of Columbia

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown


  • Quick Help: This Credit Rating Report will be emailed to you.


If you have a more general question about our products please try our



Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer, Inc.